http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1578436-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d452ebbe234b18c80d0462dc24578da3 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 |
filingDate | 2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fbb4f070a3363902d79050e3312c1f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4d7515995f5b13a9cd68779f0cc680d |
publicationDate | 2005-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1578436-A2 |
titleOfInvention | Saposing c and receptors as targets for treatment of benign and malignant disorders |
abstract | Saposin C was shown to be a trophic factor for a variety of cancer cells, e.g., prostate, lung, breast, and colon cancer cells. These cells expressed saposin C and responded to saposin C by increased levels of cell proliferation, cell migration, and cell invasion. Such activities typify and promote the neoplastic process. A conjugate of a peptide of the active region of saposin C (TX14A) and a toxin (saporin) was made and was shown to decrease the survival of prostate cancer cells, and the other cancer cells that were found to express saposin C (including cancers cells of the breast, colon, and lung). This conjugate or a compound of analogous action that inhibits cellular growth acting via a saposin-C binding receptor can be used to decrease tumor growth and/or treat disorders of stromal proliferation (e.g., benign prostatic hyperplasia, atherosclerosis, and vascular restenosis). |
priorityDate | 2002-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 486.